Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression
Therapeutic Advances in Musculoskeletal Disease · 2023-01 · 15
DOI: 10.1177/1759720x231165558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 10.04.2023. Verfasst von Ali Guermazi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, School of Medicine, Boston University, Boston, MA 02132, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Despite decades of research efforts and multiple clinical trials aimed at discovering efficacious disease-modifying osteoarthritis (OA) drugs (DMOAD), we still do not have a drug that shows convincing scientific evidence to be approved as an effective DMOAD. It has been suggested these DMOAD clinical trials were in part unsuccessful since eligibility criteria and imaging-based outcome evaluation were solely based on conventional radiography. The OA research community has been aware of the limitations of conventional radiography being used as a primary imaging modality for eligibility and efficacy assessment in DMOAD trials. An imaging modality for DMOAD trials should be able to depict soft tissue and osseous pathologies that are relevant to OA disease progression and clinical manifestations of OA. Magnetic resonance imaging (MRI) fulfills these criteria and advances in technology and increasing knowledge regarding imaging outcomes likely should play a more prominent role in DMOAD clinical trials. In this perspective article, we will describe MRI-based tools and analytic methods that can be applied to DMOAD clinical trials with a particular emphasis on knee OA. MRI should be the modality of choice for eligibility screening and outcome assessment. Optimal MRI pulse sequences must be chosen to visualize specific features of OA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, School of Medicine, Boston University, Boston, MA 02132, USA.
- VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA, USA.
- Department of Radiology, Universitätsklinikum Erlangen & Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
- Department of Radiology, School of Medicine, Boston University, Boston, MA, USA.
- Institute of Sports Imaging, Sports Medicine Department, French National Institute of Sports (INSEP), Paris, France.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Ali Guermazi, Frank W Roemer
Zitieren
APA
Guermazi, A., Roemer, F. W., Crema, M. D., Jarraya, M., Mobasheri, A., & Hayashi, D. (2023). Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression. Therapeutic Advances in Musculoskeletal Disease, 15. https://doi.org/10.1177/1759720x231165558
Vancouver
Guermazi A, Roemer FW, Crema MD, Jarraya M, Mobasheri A, Hayashi D. Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression. Therapeutic Advances in Musculoskeletal Disease. 2023;15. doi:10.1177/1759720x231165558
BibTeX
@article{Guermazi2023,
author = {Guermazi, Ali and Roemer, Frank W and Crema, Michel D and Jarraya, Mohamed and Mobasheri, Ali and Hayashi, Daichi},
title = {Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2023},
volume = {15},
doi = {10.1177/1759720x231165558}
}
EUVIMED